Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Verekitug in Severe asthma. The expected timing is based on the latest available company guidance and may change.
VALIANT trial. Ph2 LTE (VALOUR) initiated May 2025. 7/8/25- Completed enrollment. Top-line data in Q1 2026. 11/05/25:- Company confirmed it remains on track to report VALIANT Ph2 severe asthma topline results in Q1 2026. 02/11/26:- VALIANT Ph2 severe asthma topline showed significant AAER, FEV1, FeNO benefits; planning Phase 3 severe asthma. 03/01/26:- Phase 3 severe asthma registrational trial planning commenced; initiation planned after regulatory interactions. 03/26/26:- Plan to initiate severe asthma Phase 3 dosing in Q1 2027 using high-dose quarterly regimen. 05/13/26:- EoPh2 FDA meetings mid-2026; severe asthma Ph3 dosing still expected Q1 2027. VALOUR LTE completed enrollment with >90% retention. 08/11/26:- VALIANT ERS data September 5-9, 2026. Ph3 remains Q1 2027. VALOUR data H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.